Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research



Rating:

Share or cite this content

Citations should be made in the following way:
N. K.Dezfuli (Tehran, Islamic Republic of Iran), S. Alipoor (Tehran, Islamic Republic of Iran), N. Roofchayee (Tehran, Islamic Republic of Iran), S. Seyfi (Tehran, Islamic Republic of Iran), E. Mortaz (Tehran, Islamic Republic of Iran). Evaluation expression of miR-146a and miR-155 and inflammatory  cytokines in blood of non-small cell lung cancer patients. 1129

Member's Comments

No comment yet.

Related content which might interest you: Expression analysis of miR-223 in plasma of patients with non-small cell lung cancer and other obstructive lung diseases Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018 Differential cytokine expression in non-small cell lung carcinomas Source: Eur Respir J 2007; 30: Suppl. 51, 512s Year: 2007 Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer Source: Annual Congress 2009 - Lung cancer biology Year: 2009 Impact of PD-L1 expression levels on the response to pembrolizumab in metastatic non-small cell lung cancer> Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer Year: 2021 Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer Source: Eur Respir J 2007; 30: 627-632 Year: 2007 Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival Source: Eur Respir J 2011; 37: 617-623 Year: 2011 The value of CD44 and MMP-2 expression in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004 Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy Source: Eur Respir J, 53 (3) 1801562; 10.1183/13993003.01562-2018 Year: 2019 Survivin expression in non-small cell lung cancer Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Pleural and systemic cytokine expression profiles in patients with lung cancer Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Relationship between blood monocyte subsets with activation markers and macrophages in non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10 Source: Eur Respir J 2007; 30: 608-610 Year: 2007 Expression of ERCC1 in normal and tumor tissues in non-small cell lung cancer Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007 Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer Source: Eur Respir J 2013; 41: 1172-1178 Year: 2013 Choice of endogenous control for gene expression in nonsmall cell lung cancer Source: Eur Respir J 2005; 26: 1002-1008 Year: 2005 Abnormal expression of let-7a miRNA in blood of lung cancer patient Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC) Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro Year: 2020 Apelin expression is a prognostic factor in non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Evaluate soluble PD-L1 in plasma in advanced stage non-small cell lung cancer patients Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020 Expression of βig-h3 as a marker of local tumor invasion in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 770s Year: 2006